Form 4: AIM ImmunoTech Director Acquires Shares as Compensation
SEC Form 4 Filing
AIM ImmunoTech director William M Mitchell acquired 24,452 shares of common stock as compensation under the company's Cash Conservation Plan.
Summary
- Director William M Mitchell acquired 24,452 shares of AIM ImmunoTech common stock on December 13, 2024.
- The shares were acquired at a price of $0.213 per share.
- This transaction increased Mitchell's direct holdings to 123,803 shares.
- The shares were issued in lieu of director compensation as part of the company's Cash Conservation Plan.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it shows a director's increased stake in the company, but it is also a result of a cash conservation plan which may indicate financial constraints.
Positives
- The acquisition of shares by a director demonstrates confidence in the company.
- The use of shares for compensation helps conserve cash for the company.
Management Comments
- The shares acquired on the Transaction Date were issued in lieu of director compensation pursuant to the issuer's Cash Conservation Plan.
Industry Context
This type of transaction is common in publicly traded companies where directors are often compensated with equity to align their interests with shareholders and conserve cash.
Comparison to Industry Standards
- Director compensation in the form of stock is a common practice across the industry, particularly for smaller companies looking to conserve cash.
- Many biotech companies use stock options and grants as part of their compensation packages for directors and executives.
- The specific amount of shares and the price are specific to AIM ImmunoTech and its current valuation.
Stakeholder Impact
- Shareholders may view this as a positive sign of director alignment with company interests.
- The company benefits from conserving cash by issuing shares instead of cash compensation.
Key Dates
| Date | Description |
|---|---|
| 12/13/2024 | Date of the share acquisition by director William M Mitchell. |
| 12/17/2024 | Date of signature on the SEC Form 4 filing. |
Keywords
AIM ImmunoTech, Director, Share Acquisition, Compensation, Cash Conservation Plan, Common Stock, Form 4, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.